Cargando…

Low dose rate prostate brachytherapy

Low dose rate (LDR) prostate brachytherapy is an evidence based radiation technique with excellent oncologic outcomes. By utilizing direct image guidance for radioactive source placement, LDR brachytherapy provides superior radiation dose escalation and conformality compared to external beam radiati...

Descripción completa

Detalles Bibliográficos
Autores principales: Stish, Bradley J., Davis, Brian J., Mynderse, Lance A., McLaren, Robert H., Deufel, Christopher L., Choo, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043740/
https://www.ncbi.nlm.nih.gov/pubmed/30050795
http://dx.doi.org/10.21037/tau.2017.12.15
_version_ 1783339346318852096
author Stish, Bradley J.
Davis, Brian J.
Mynderse, Lance A.
McLaren, Robert H.
Deufel, Christopher L.
Choo, Richard
author_facet Stish, Bradley J.
Davis, Brian J.
Mynderse, Lance A.
McLaren, Robert H.
Deufel, Christopher L.
Choo, Richard
author_sort Stish, Bradley J.
collection PubMed
description Low dose rate (LDR) prostate brachytherapy is an evidence based radiation technique with excellent oncologic outcomes. By utilizing direct image guidance for radioactive source placement, LDR brachytherapy provides superior radiation dose escalation and conformality compared to external beam radiation therapy (EBRT). With this level of precision, late grade 3 or 4 genitourinary or gastrointestinal toxicity rates are typically between 1% and 4%. Furthermore, when performed as a same day surgical procedure, this technique provides a cost effective and convenient strategy. A large body of literature with robust follow-up has led multiple expert consensus groups to endorse the use of LDR brachytherapy as an appropriate management option for all risk groups of non-metastatic prostate cancer. LDR brachytherapy is often effective when delivered as a monotherapy, although for some patients with intermediate or high-risk disease, optimal outcome are achieved in combination with supplemental EBRT and/or androgen deprivation therapy (ADT). In addition to reviewing technical aspects and reported clinical outcomes of LDR prostate brachytherapy, this article will focus on the considerations related to appropriate patient selection and other aspects of its use in the treatment of prostate cancer.
format Online
Article
Text
id pubmed-6043740
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-60437402018-07-26 Low dose rate prostate brachytherapy Stish, Bradley J. Davis, Brian J. Mynderse, Lance A. McLaren, Robert H. Deufel, Christopher L. Choo, Richard Transl Androl Urol Review Article Low dose rate (LDR) prostate brachytherapy is an evidence based radiation technique with excellent oncologic outcomes. By utilizing direct image guidance for radioactive source placement, LDR brachytherapy provides superior radiation dose escalation and conformality compared to external beam radiation therapy (EBRT). With this level of precision, late grade 3 or 4 genitourinary or gastrointestinal toxicity rates are typically between 1% and 4%. Furthermore, when performed as a same day surgical procedure, this technique provides a cost effective and convenient strategy. A large body of literature with robust follow-up has led multiple expert consensus groups to endorse the use of LDR brachytherapy as an appropriate management option for all risk groups of non-metastatic prostate cancer. LDR brachytherapy is often effective when delivered as a monotherapy, although for some patients with intermediate or high-risk disease, optimal outcome are achieved in combination with supplemental EBRT and/or androgen deprivation therapy (ADT). In addition to reviewing technical aspects and reported clinical outcomes of LDR prostate brachytherapy, this article will focus on the considerations related to appropriate patient selection and other aspects of its use in the treatment of prostate cancer. AME Publishing Company 2018-06 /pmc/articles/PMC6043740/ /pubmed/30050795 http://dx.doi.org/10.21037/tau.2017.12.15 Text en 2018 Translational Andrology and Urology. All rights reserved.
spellingShingle Review Article
Stish, Bradley J.
Davis, Brian J.
Mynderse, Lance A.
McLaren, Robert H.
Deufel, Christopher L.
Choo, Richard
Low dose rate prostate brachytherapy
title Low dose rate prostate brachytherapy
title_full Low dose rate prostate brachytherapy
title_fullStr Low dose rate prostate brachytherapy
title_full_unstemmed Low dose rate prostate brachytherapy
title_short Low dose rate prostate brachytherapy
title_sort low dose rate prostate brachytherapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043740/
https://www.ncbi.nlm.nih.gov/pubmed/30050795
http://dx.doi.org/10.21037/tau.2017.12.15
work_keys_str_mv AT stishbradleyj lowdoserateprostatebrachytherapy
AT davisbrianj lowdoserateprostatebrachytherapy
AT mynderselancea lowdoserateprostatebrachytherapy
AT mclarenroberth lowdoserateprostatebrachytherapy
AT deufelchristopherl lowdoserateprostatebrachytherapy
AT choorichard lowdoserateprostatebrachytherapy